Size and apolipoprotein composition are the main factors determining atherogenicity of triglyceride-rich particles.

Slides:



Advertisements
Similar presentations
Residual risk: Is LDL target enough?
Advertisements

Lipoprotein Metabolism And Disorders
ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.
Genetics of Lipoprotein Disorders
Bart Staels INSERM UR545; Institut Pasteur de Lille; Université Lille Nord de France Lille, France Triglycerides as a Risk Factor for Cardiovascular Disease.
COMPOSITION OF LIPIDS Lipoproteins Apolipoproteins Lipoproteins Apolipoproteins Cholesterol Protein Triglyceride Phospholipid.
LIVER Glucose can can NOT be made from fatty acids Glucose
Friend or Foe? High HDL Cholesterol. High Density Lipoprotein Origin: liver Content: 18-25% TC content 45-55% Protein 2-7% TG 20-30% Phospholipids Density:
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
Lipoprotein Structures, Function and Metabolism (1)
Lipids (Lipid Profile)
Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.
LIPOPROTEIN Mpenda F.N.
Lipoproteins Metabolism
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Diabetic Dyslipidemia and Atherosclerosis Henry Ginsberg, MD
THE LIPID PANEL What are we missing? Robert St. Amant, MD, FAAFP Diplomate, American Board of Clinical Lipidology Baton Rouge General Medical Director,
Lipoproteins Clusters of lipids associated with proteins that serve as transport vehicles for lipids in the lymph and blood.
Aims 1.Outline the structural diversity of lipids. 2.Examine the biophysical characteristics of lipids. 3Outline the biochemical synthesis of fatty acids,
Lipoproteins/Particles
1 LIPID TRANSPORT Lipoproteins Lipids are transported in the blood as lipoproteins are soluble in water because the surface consists of polar lipids.
Cholesterol is among the lipids (fats) in the bloodstream. Source: Supplied from diet or synthesized by liver. Importance: 1.Form cell membranes and.
Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:
بسم الله الرحمن الرحيم.
بسم الله الرحمن الرحيم.
ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.
Clinical diagnostic biochemistry - 8
HANDBOOK OF DYSLIPIDEMIA AND ATHEROSCLEROSIS Part One Professor Jean-Charles Fruchart Department of Atherosclerosis (Inserm UR545) Pasteur Institute of.
Drugs Used in Hyperlipidemia
Lipoproteins A lipoprotein is a biochemical assembly that contains both proteins and lipids, bound to the proteins, which allow fats to move through the.
Upon entry into the circulation, chylomicrons (containing apo B-48) produced by the small intestine, and VLDL (containing apo B-100) produced by the liver.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
Apolipoproteins as markers and managers of coronary risk by D.C. Chan, and G.F. Watts QJM Volume 99(5): April 24, 2006 © The Author Published.
Lipoprotein Structure, Function, and Metabolism
Therapeutic Lifestyle
Hyperlipidemias.
بسم الله الرحمن الرحيم.
Arabinda Mohan Bhattarai, MBBS, MD (Biochemistry) Asst Prof, NAIHS
TOTAL CHOLESTEROL.
THE MANY FUNCTIONS OF INSULIN IN LIPID METABOLISM
Atherosclerosis, Plaque Imaging
The effects of apo E alleles on various lipoprotein parameters
Plasma LIPOPROTEINS METABOLISM & DISORDERS Basil OM Saleh
Lipoprotein(a), Cardiovascular Disease, and Contemporary Management
LIPIDS AND LIPOPROTEINS Dr. Gamal Gabr
HDL and Atherosclerosis
Paul Durrington  Atherosclerosis Supplements 
by Kiran Musunuru, and Sekar Kathiresan
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
Review of Cholesterol and Lipoproteins
Figure 7 Mendelian randomization of overlapping exposures
Genes and environment in type 2 diabetes and atherosclerosis
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Type 2 diabetes: Overlap of clinical conditions
Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.
Lipoproteins and cholesterol
HDL and Atherosclerosis
Jonathan C. Cohen, PhD  Journal of Clinical Lipidology 
بسم الله الرحمن الرحيم.
K June 03 03/06/20 1.
Volume 12, Issue 2, Pages (August 2010)
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
Figure 1 The major pathways of lipid metabolism
New insights into lipid metabolism in the nephrotic syndrome
Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication.
Schematic representation of dyslipidaemia of metabolic syndrome.
Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.
Reverse cholesterol transport CETP is key in remodeling of HDL
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

Size and apolipoprotein composition are the main factors determining atherogenicity of triglyceride-rich particles

Apo C-III modulates VLDL

Apo C-III in apo B particles is atherogenic

Relationship between apo C-III in apo B containing lipoproteins and atherogenicity

PROCAM Study MI-Incidence according to LDL-cholesterol and triglycerides

PROCAM Study CHD risk according to LDL-C and TG increased TG confers raised CHD risk at all levels of LDL-C

HDL: an anti-atherogenic lipoprotein

HDL metabolism: 5 key genes

HDL: apo AI-rich particles

Apo A-I protects against atherosclerosis

Apo A-II protects against atherosclerosis The human apo A-II transgenic mouse model